로딩 중...
52주 최고가 대비 88.6% 위치
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|
| 주요 재무실적 (USD) | ||||
| 매출액 | $79.99B | $85.16B | $88.82B | $94.19B |
| 영업이익 | $21.01B | $22.01B | $21.25B | $25.60B |
| 당기순이익 | $17.94B | $35.15B | $14.07B | $26.80B |
| 잉여현금흐름 (FCF) | $17.18B | $17.78B | $18.06B | $19.31B |
| 수익성 비율 | ||||
| 영업이익률 | 26.3% | 25.8% | 23.9% | 27.2% |
| 순이익률 | 22.4% | 41.3% | 15.8% | 28.5% |
| ROE (자기자본이익률) | 23.4% | 51.1% | 19.7% | 32.9% |
| ROA (자산이익률) | 9.6% | 21.0% | 7.8% | 13.5% |
| 성장성 비율 | ||||
| 매출 성장률 (YoY) | - | 6.5% | 4.3% | 6.0% |
| EPS 성장률 (YoY) | - | 103.9% | -57.8% | 90.5% |
| 투자 지표 & 가치배수 | ||||
| PER (주가수익배수) | 21.9x | 10.8x | 25.2x | 20.4x |
| PBR (주가순자산배수) | 4.6x | 5.2x | 4.9x | 6.6x |
| PSR (주가매출배수) | 4.4x | 4.2x | 4.0x | 5.7x |
| FCF Yield | 4.8% | 5.0% | 5.1% | 3.6% |
| 재무 건전성 (안정성) | ||||
| 부채비율 (D/E) | 0.52 | 0.43 | 0.51 | 0.59 |
| 유동비율 | 0.99 | 1.16 | 1.11 | 1.03 |
MOLINA HEALTHCARE INC
$179.86
$9.4B